Table 1 (abstract P48). Outcomes at follow-up

Decrease in VAS well-being compared to baseline, median (IQR)

2.0 (0.0 – 4.0)

2.0 (0.1 – 5.0)

-0.81 (-1.72 – 0.08)^a

Decrease in active joint count compared to baseline, median (IQR)

2.5 (1.0 – 4.0)

2.0 (1.0 – 6.0)

n = 45

0.44 (-0.22 – 1.10)^a

Adverse events, n (%)

15 (34.1%)

n = 44

13 (28.3%)

1.82 (0.59 – 5.60)^b

Uveitis events, n (%)

0 (0.0%)

1 (2.2%)

-